A detailed history of State Street Corp transactions in Lyra Therapeutics, Inc. stock. As of the latest transaction made, State Street Corp holds 488,720 shares of LYRA stock, worth $87,969. This represents 0.0% of its overall portfolio holdings.

Number of Shares
488,720
Previous 259,820 88.1%
Holding current value
$87,969
Previous $72,000 76.39%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.24 - $0.34 $54,936 - $77,826
228,900 Added 88.1%
488,720 $127,000
Q2 2024

Aug 14, 2024

BUY
$0.26 - $6.25 $34,746 - $835,250
133,640 Added 105.91%
259,820 $72,000
Q1 2024

May 15, 2024

BUY
$4.55 - $6.53 $77,350 - $111,010
17,000 Added 15.57%
126,180 $784,000
Q4 2023

Feb 14, 2024

BUY
$2.82 - $5.24 $39,762 - $73,884
14,100 Added 14.83%
109,180 $572,000
Q3 2023

Nov 14, 2023

BUY
$2.95 - $4.8 $115,935 - $188,640
39,300 Added 70.46%
95,080 $371,000
Q2 2023

Aug 14, 2023

BUY
$1.98 - $4.33 $36,036 - $78,806
18,200 Added 48.43%
55,780 $229,000
Q4 2022

Feb 14, 2023

BUY
$2.44 - $5.42 $6,190 - $13,750
2,537 Added 7.24%
37,580 $118,000
Q3 2022

Nov 15, 2022

BUY
$4.95 - $6.6 $3,960 - $5,280
800 Added 2.34%
35,043 $176,000
Q2 2022

Aug 15, 2022

BUY
$4.12 - $7.51 $141,081 - $257,164
34,243 New
34,243 $193,000
Q2 2021

Aug 16, 2021

SELL
$6.91 - $12.59 $665,059 - $1.21 Million
-96,246 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$10.38 - $15.61 $193,068 - $290,346
18,600 Added 23.95%
96,246 $1.12 Million
Q4 2020

Feb 16, 2021

BUY
$9.28 - $13.88 $298,259 - $446,103
32,140 Added 70.63%
77,646 $885,000
Q3 2020

Nov 10, 2020

BUY
$10.61 - $13.96 $32,519 - $42,787
3,065 Added 7.22%
45,506 $509,000
Q2 2020

Aug 14, 2020

BUY
$10.91 - $18.56 $463,031 - $787,704
42,441 New
42,441 $481,000

Others Institutions Holding LYRA

About Lyra Therapeutics, Inc.


  • Ticker LYRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,826,400
  • Market Cap $5.73M
  • Description
  • Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained...
More about LYRA
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.